27-Jan-2026
TipRanks (Mon, 26-Jan 4:25 PM ET)
SI-BONE Projects 20% Revenue Growth in 2025—Physician Base and Cash Reserves Also Expand
Market Chameleon (Mon, 12-Jan 4:39 AM ET)
SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
Globe Newswire (Mon, 12-Jan 9:00 AM ET)
SI-BONE To Present at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025
Globe Newswire (Tue, 18-Nov 4:09 PM ET)
SIBN Lifts 2025 Outlook After Delivering 21% Revenue Growth and Positive Cash Flow
Market Chameleon (Tue, 11-Nov 6:15 AM ET)
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance
Globe Newswire (Mon, 10-Nov 4:09 PM ET)
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
Si-Bone trades on the NASDAQ stock market under the symbol SIBN.
As of January 27, 2026, SIBN stock price declined to $17.03 with 476,754 million shares trading.
SIBN has a beta of 0.40, meaning it tends to be less sensitive to market movements. SIBN has a correlation of 0.02 to the broad based SPY ETF.
SIBN has a market cap of $738.95 million. This is considered a Small Cap stock.
Last quarter Si-Bone reported $49 million in Revenue and -$.11 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.05.
In the last 3 years, SIBN traded as high as $29.51 and as low as $11.70.
The top ETF exchange traded funds that SIBN belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
SIBN has underperformed the market in the last year with a price return of +4.8% while the SPY ETF gained +15.6%. However, in the short term, SIBN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +9.9% vs +3.0% return in SPY. But in the last 2 weeks, SIBN shares have been beat by the market, returning -4.7% compared to an SPY return of 0.0%.
SIBN support price is $16.65 and resistance is $17.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SIBN shares will trade within this expected range on the day.